All In MedTech

FDA Clearance Tracker · P990056-S039

Elecsys total PSA, total PSA CalSet II

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 23, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 23, 2023

Approved

Time to decision

177 days

Received Sep 27, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990056-S039
Device name
Elecsys total PSA, total PSA CalSet II
Applicant location
Indianapolis, IN
Received
Sep 27, 2022
Decided
Mar 23, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990056

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

Approval to extend application of the Elecsys total PSA immunoassay onto the cobas e 402 immunoassay analyzer

Source documents

Other decisions for Roche Diagnostics Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.